Improved functional cardiac MR imaging using the intravascular contrast agent CLARISCAN
- PMID: 14598903
- DOI: 10.1023/a:1025432415983
Improved functional cardiac MR imaging using the intravascular contrast agent CLARISCAN
Abstract
Purpose: Using segmented k-space turbo gradient echo MR techniques (TGE) contrast between blood and myocardium is often reduced in long axis views due to reduced in plane spin-refreshment, particularly in patients with low ejection fraction. The application of an intravascular contrast agent (CA) may improve endocardial border delineation.
Materials and methods: In 15 patients cardiac cine loops in two long axis and two short axis views were acquired during breath hold using a TGE sequence without and with increasing doses of CA (0.75, 2.0, 5.0 mg Fe/kg). Two independent observers evaluated left ventricular function (LVEF, modified Simpson's rule) and assigned a visual score (range: 0 = 'not visualized' to 6 = 'excellent visualization') for endocardial border delineation. Signal- and contrast-to-noise ratios (SNR; CNR) were determined.
Results: Endocardial border delineation score for TGE was 1.7 +/- 0.6 and 3.9 +/- 0.6**, 4.4 +/- 0.5**, 4.6 +/- 0.4** for 0.75, 2.0, 5.0 mg Fe/kg of CA, respectively (**p < 0.01 vs. TGE). SNR of blood increased significantly with any dose of CA with a mild drop of myocardial SNR resulting in a significant increase of CNR blood/myocardium. The maximum effect with 2.0 mg Fe/kg was a >2-fold CNR increase. Inter- and intraobserver variability assessed according to the method of Bland-Altmann was reduced at 2.0 mg Fe/kg for determination of LVEF and reached statistical significance for LVEF <50%.
Conclusion: Intravascular CA increased CNR between blood and myocardium by a factor >2 and significantly improved the determination of cardiac volumes. The benefit in accuracy was most for patients with left ventricular ejection fraction <50%.
Similar articles
-
Use of an intravascular T1 contrast agent to improve MR cine myocardial-blood pool definition in man.J Magn Reson Imaging. 1997 Jul-Aug;7(4):765-7. doi: 10.1002/jmri.1880070425. J Magn Reson Imaging. 1997. PMID: 9243400
-
Improvement of image quality of non-invasive coronary artery imaging with magnetic resonance by the use of the intravascular contrast agent Clariscan (NC100150 injection) in patients with coronary artery disease.J Magn Reson Imaging. 2003 Jun;17(6):656-62. doi: 10.1002/jmri.10317. J Magn Reson Imaging. 2003. PMID: 12766894 Clinical Trial.
-
Breath-hold 3D MR coronary angiography with a new intravascular contrast agent (feruglose)--first clinical experiences.Magn Reson Imaging. 2001 Feb;19(2):201-5. doi: 10.1016/s0730-725x(01)00295-8. Magn Reson Imaging. 2001. PMID: 11358658 Clinical Trial.
-
Characterization of t1 relaxation and blood-myocardial contrast enhancement of NC100150 injection in cardiac MRI.J Magn Reson Imaging. 1999 Nov;10(5):784-9. doi: 10.1002/(sici)1522-2586(199911)10:5<784::aid-jmri24>3.0.co;2-a. J Magn Reson Imaging. 1999. PMID: 10548789
-
Multislice breath-hold spiral magnetic resonance coronary angiography in patients with coronary artery disease: effect of intravascular contrast medium.J Magn Reson Imaging. 2002 Dec;16(6):660-7. doi: 10.1002/jmri.10202. J Magn Reson Imaging. 2002. PMID: 12451579
Cited by
-
Measurement of left ventricular dimensions with contrast-enhanced three-dimensional cine imaging facilitated by k-t SENSE.J Cardiovasc Magn Reson. 2008 May 28;10(1):27. doi: 10.1186/1532-429X-10-27. J Cardiovasc Magn Reson. 2008. PMID: 18507849 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Medical